| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
– Independent Safety Monitoring Committee recommended advancement of SER-252 in Parkinson's disease to Cohort 2 |
| 12 Nov 2026 | 10-Q |
| 03 Nov 2026 | SCHEDULE 13G/A |
| 09 Oct 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
State of Delaware Secretary of State Division of Corporations Delh•ered 12 :22 P:\1 10/05/2026 FILED 12:22 PM 10/05/2026 SR 20264597278 - File Number 6241730 CERTIFICATE OF ELIMINATION OF SERIES A CONVERTIBLE PREFERRED STOCK OF SERINA TH... |
| 09 Sep 2026 |
8-K: Other Events
Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2 |
| 31 Aug 2026 | EFFECT |
| 27 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
On August 21, 2026, Serina Therapeutics, Inc. (the “Company”) entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) and a related Registration Rights Agreement (the “Registration Rights Agreement”), each dated as of A... |
| 24 Aug 2026 | S-1 |
| 13 Aug 2026 | S-8 |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
–Enrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252 - |
| 13 Aug 2026 | 10-Q |
| 23 Jul 2026 |
Form 4: Simon Farrell, Director
Granted 30,500 Stock Option (right to buy) |
| 23 Jul 2026 |
Form 3: Simon Farrell, Director
No securities owned |
| 23 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Amended and Restated Employment Agreement (this “Agreement”) is made and entered into effective as of the 19th day of July, 2026 (the “Restatement Date”), by and between (i) Serina Therapeutics, Inc., a Delaware corporation (“Serina... |
| 22 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
HUNTSVILLE, Ala., July 22, 2026, (GLOBE NEWSWIRE) – Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company advancing its proprietary POZ Platform™ drug optimization technology, ... |
| 22 Jul 2026 | SCHEDULE 13D/A |
| 09 Jul 2026 |
Form 4: Brannan Stephen K., Director
Bought 1,000 shares ($2.03K) |
| 24 Jun 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
THIS AMENDMENT TO THE SERINA THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN (this “Amendment”) is effective as of June 17, 2026. Capitalized terms used and not defined herein shall have the meanings ascribed to them in the Plan (as define... |
| 22 Jun 2026 |
Form 4: Venkatesan Jay, Director
Bought 589 shares ($1.05K) · Received 224,152 shares by conversion ($504K) · Granted 15,250 Stock Option (right to buy) |
| 22 Jun 2026 |
Form 4: Bailey Gregory, Director
Received 8,437,472 shares by conversion ($19M) · Granted 15,250 Stock Option (right to buy) · Granted 3,333,333 Redeemable Warrants |
Loading...